Background
==========

Over the past decade an increasing number of single nucleotide polymorphisms (SNPs) in the β~2~-adrenoceptor (β~2~-AR) gene have been identified. Initially the focus of research was on two highly prevalent non-synonymous SNPs in the coding region of the gene that both result in an amino acid substitution in the extra-cellular part of the receptor protein: position 16 Arg→Gly and position 27 Gln→Glu. *In vitro*these amino acid changes appeared to alter the susceptibility to receptor downregulation by exposure to β~2~-agonists \[[@B1],[@B2]\]. These observations fuelled a number of clinical and *in vitro/ex vivo*studies yielding inconsistent and sometimes conflicting results. Arg-16 was found to be associated with a greater acute bronchodilator response to a β~2~-AR agonist \[[@B3],[@B4]\], but also with loss of asthma control in some studies \[[@B5],[@B6]\], but not in all \[[@B7]\]. In an *ex vivo*study using human peripheral blood lymphocytes no impact of either polymorphism could be substantiated on baseline receptor expression or responsiveness\[[@B8]\].

It is generally assumed that the *in vivo*consequence of the downregulation of β~2~-ARs is tolerance towards the airway smooth muscle mediated effects of β~2~agonists. This tolerance has generally been difficult to show for the bronchodilator effects of β~2~-AR agonists, but is more pronounced and potentially clinically relevant for their bronchoprotective effects \[[@B9]\]. The relationship between the polymorphic amino acids 16 and 27 and the susceptibility to bronchodilator tolerance was the subject of two clinical studies \[[@B10],[@B11]\], but in only one of these such an association could be substantiated \[[@B10]\]. Tolerance development towards the bronchoprotective effects of β~2~-agonists was the subject of two prospective clinical studies, which did not find differences between amino acid 16 genotypes \[[@B12],[@B13]\]. Results of *in vitro*studies using either human mast cells or airway smooth muscle cells did not aid in settling the issue \[[@B14],[@B15]\].

More recently additional SNPs in the non-coding regulatory part of the β~2~-AR gene were described, some of which affect receptor expression and regulation *in vitro*\[[@B16]-[@B18]\]. These SNPs are in strong linkage disequilibrium with those coding for amino acid 27 in the β~2~-AR protein, which results in only a very limited variation in extended allelic haplotypes \[[@B16],[@B18],[@B19]\]. *In vitro*studies initially focused on the SNPs in the 5\' flanking region of the receptor coding block in isolation. Analysis of the relative promoter activities of serially truncated fragments of the 5\' flanking region suggested that the regulatory activity of the β~2~-AR gene is largely concentrated in the region of 550 base pair 5\' to the coding block. In particular, deletion of the region containing the -367 SNP strongly reduced transcription. In a comparative assay, alleles containing the -367 T→ C mutation were shown to result in a lower transcription rate (\~17%) \[[@B18]\]. Recently, we were able to confirm this finding and showed that this was associated with the decreased binding of an as yet unidentified transcription factor \[[@B20]\].

The intronless coding region of the β~2~-AR protein is preceded by a small open reading frame encoding a 19 amino acid peptide, the β~2~-AR upstream peptide (BUP), which inhibits β~2~-AR mRNA translation \[[@B17]\]. The -47 C/T SNP leads to a Cys → Arg substitution at position 19 of the BUP. Transfection experiments with constructs containing either variant of this SNP showed that Cys19 resulted in an increase in receptor protein expression through an effect on mRNA translation \[[@B16]\]. However, when the BUP SNP was studied in the context of a validated haplotype, the BUP Cys19 allele was associated with decreased receptor protein and mRNA expression, which appeared to be associated with a decreased bronchodilator response to an inhaled β~2~-agonist in a cross-sectional study in a cohort of asthmatics \[[@B19]\]. On the basis of this latter observation these authors advocated studying the biological phenotypic consequences of the β~2~-AR SNPs only within the context of validated haplotypes. In fact, our study extends on this study. For our functional analyses we limited the haplotypes to the SNPs in the 5\'region of the gene, of which an influence on transcription and regulation may be expected, combined with the two far most prevalent non-synonymous SNPs in the receptor protein coding block at +46 and +79.

Our primary aim was to study the impact of different combinations of allelic haplotypes on tolerance to β~2~-agonist induced bronchoprotection. To this end, we conducted a double blind cross-over study of two-week treatment periods with either the short-acting β~2~-agonist terbutaline or a matching placebo. Cumulative dose response curves of the full β~2~-AR agonist fenoterol versus PD~20~methacholine were used as the main physiologic endpoint.

We found differences between six distinct β~2~-AR allelic genotypes in the shape of the dose response relationship and in the propensity to develop tolerance for these effects. These differences are statistically significant and functionally relevant only for bronchoprotection when compared to bronchodilation in terms of recovery from metacholine induced bronchoconstriction. The magnitudes of the net differences are, however, unlikely to be of clinical significance

Methods
=======

Patients
--------

Recruitment of patients with mild to moderate asthma and inclusion criteria have been described in detail elsewhere \[[@B21]\]. According to current guidelines all patients used inhaled corticosteroids, of which the dose was kept stable from at least 8 weeks prior to inclusion until the end of the study. If inclusion criteria were met, a blood sample was drawn for isolation of DNA. All subjects gave written informed consent to participate in the study that was approved by the Medical Ethics Committee of the Academic Medical Centre in Amsterdam.

Design
------

The study had a randomized, placebo-controlled, double-blind, cross-over design. Two treatment periods of two weeks were preceded and separated by wash-out periods of two weeks, during which all β~2~-agonists were discontinued and only ipratropium bromide pressurized metered dose inhaler (pMDI) was allowed for symptom relieve. During the treatment periods a dry powder inhaler (Turbuhaler^®^, Astra-Zeneca, Zoetermeer, the Netherlands) containing either 500 μg of terbutaline per inhalation or placebo was used four times daily. The subjects attended to the laboratory 24 hours after the last dose of study medication and after ipratropium bromide had been withheld for at least 8 hours. After baseline FEV~1~and PD~20~methacholine had been determined, subjects inhaled 200 μg of fenoterol pMDI from an aerochamber as the first of a series of 4 doubling doses, resulting in cumulative doses of 200, 600, 1400, and 3000 μg respectively. One hour after each dose of fenoterol a PD~20~methacholine was determined, immediately after which the next dose of fenoterol was inhaled. Lung function measurements and methacholine provocation tests were done as described previously \[[@B21]\].

Assessment of extended β~2~-adrenoceptor genotypes
--------------------------------------------------

Genomic DNA was extracted from peripheral blood mononuclear cells. Using allele-specific primers distinguishing between the -367T- and -367C-alleles, DNA was amplified by PCR, applying standard conditions. The fragment between nucleotides -367 and + 377 was amplified using sense primers 7 or 8 (Table [1](#T1){ref-type="table"}) and anti-sense primer 2, and the fragment between -367 and -1081 was amplified with anti-sense primers 215 or 216 and sense primer 214. The PCR products were separated by agarose gel electrophoresis and isolated from the gel. Using the same -367 haplotype-specific primer sets, the sequence of the PCR products was determined by automatic sequencing. In case of -367 homozygous patients within the cohort studied, heterozygous polymorphisms downstream or upstream were limited to the +46 SNP, thus still allowing for the assessment of the full haplotypes.

###### 

Primers used for allele-specific PCR amplification and sequencing.

  Primer   Fragment      direction   Sequence
  -------- ------------- ----------- -----------------------------------
  2        +396/+377     Antisense   5\'-gtagcgatccactgcgatca-3\'
  7        -387/-367     Sense       5\'-gggccccgcccgggccagcc**t**-3\'
  8        -387/-367     Sence       5\'-gggccccgcccgggccagcc**c**-3\'
  214      -1081/-1061   Antisense   5\'-ctgcaaattcctaaggagggc-3\'
  215      -349/-367     Antisense   5\'-ctcgccctccttctcctg**a**-3\'
  216      -349/-367     Antisense   5\'-ctcgccctccttctcctg**g**-3\'

Statistical analysis
--------------------

Patients were divided into subgroups according to their established allelic genotypes, based on combinations of the three found limited allelic haplotypes I, II, and III. FEV~1~values are presented as % predicted, methacholine provocation test results as (geometric mean) PD~20~(μg). Baseline FEV~1~and PD~20~are those measured after a two week wash out period followed by a two week placebo treatment period and before administration of the first dose of fenoterol.

Because of the markedly skewed distribution of PD~20~values, these were logarithmically transformed prior to analysis. Analysis of the dose response curves was based on a repeated measurement analysis of covariance with log(PD~20~) or FEV~1~(% predicted) as dependent variable, fenoterol dose, treatment (terbutaline vs. placebo), combined allelic genotype and period as factors, baseline log(PD~20~) or FEV~1~respectively as a covariate and patient as subject within whom repeated measurements may be correlated. An unstructured covariance matrix was used, implying possible differences in SD\'s at the 8 different fenoterol doses by treatment combinations, as well as varying within-patient correlations between these 8 measurements (heteroscedastic). In the model, all possible interactions were allowed between the three factors fenoterol dose, treatment (terbutaline vs. placebo) and combined allelic genotype. P-values were calculated from a Wald-based F-test with denominator degrees of freedom from the \"within-between\" method. The analysis comprised a total of 8 global model and 6 within-genotype comparisons and associated P-values. Standard, P-values were not adjusted for multiple comparisons.

For PD~20~results (means and means ± SE\'s) from the analyses were back-transformed to the normal scale. The statistical package SAS 8.2 was used for the calculations.

Results
=======

Patient characteristics
-----------------------

A total of 50 patients were enrolled of whom 45 (11 male/ 34 female), with a mean FEV~1~of 84.6 % predicted, and a geometric mean PD~20~methacholine of 163 μg completed the study. Two patients discontinued the study because of side effects of the study medication (palpitations and tremor). Two patients were excluded because of not allowed use of β~2~-AR agonist as was one female patient that turned out to be pregnant during the course of the study.

The cohort of the 45 patients that completed the study comprised 5 haplotypes within the part of the β~2~-AR gene between nucleotides -1023 and + 79 (table [2](#T2){ref-type="table"}), two of which occurred only single, one of which (Ic) has not been described previously. As described by others, linkage disequilibrium was found between nucleotides -367 T/C, -47 T/C (coding for Arg/Cys19 of the 5\' leader peptide (5\'LP)), -20 T/C and + 46 A/G (coding for Glu/Gln27 of the β~2~AR protein). This resulted in the presence within the cohort of only 3 limited haplotypes with considerably differences in (relative) frequencies (table [3](#T3){ref-type="table"}). Baseline patient characteristics of these combined limited allelic haplotypes (or allelic genotypes) (table [3](#T3){ref-type="table"}) as well as those of the subgroups based upon the amino acid 16 and 27 polymorphisms displayed no statistically significant differences.

###### 

Localization of SNPs and delineation of haplotypes of the β2-AR gene in the cohort. The limited haplotypes correspond to the SNPs in boldface. Haplotypes between brackets correspond to those of Drysdale et al.

  Nucleotide:               -1023   -654   -468   **-367**   **-47**   **-20**   **46**   **79**        
  ------------------------- ------- ------ ------ ---------- --------- --------- -------- -------- ---- ------
  III Arg19Gly16Glu27 (2)   A       G      G      C          C         C         G        G        39   43,3
  Ia Cys19Arg16Gln27 (4)    G       A      C      T          T         T         A        C        36   40
  II Cys19 Gly16Gln27 (6)   G       A      C      T          T         T         G        C        13   14,4
  Ib Cys19Arg16Gln27 (1)    A       G      C      T          T         T         A        C        1    1,1
  Ic Cys19Arg16Gln27 (x)    G       G      G      T          T         T         A        C        1    1,1

###### 

Frequencies and patient characteristics of the subgroups formed by the combined limited allelic hap1otypes. Baseline FEV~1~and PD~20~were measured after a two week washout period followed by a two week placebo treatment period, before administration of the first dose of fenoterol.

  ***Genotype***   Frequency   Baseline FEV~1~(% of predicted), mean (range)   Baseline PD~20~geometric, mean (range)   Inhalation steroid dose, mean (range)
  ---------------- ----------- ----------------------------------------------- ---------------------------------------- ---------------------------------------
  I/III            14 (31%)    85 (59 -- 107)                                  141 (24 -- 761)                          470 (200 -- 1200)
  III/III          10 (22%)    86 (54 -- 104)                                  313 (92 -- 1240)                         440 (200 -- 1000)
  II/III           5 (11%)     81 (72 -- 99)                                   110 (20 -- 371)                          380 (200 -- 500)
  I/I              10 (22%)    85 (60 -- 101)                                  176 (29 -- 672)                          530 (200 -- 1000)
  I/II             4 (9%)      82 (70 -- 94)                                   74 (30 -- 157)                           500 (400 -- 800)
  II/II            2 (4%)      88 (82 -- 93)                                   148 (33 -- 668)                          500 (200 -- 800)

Influence of the genetic polymorphisms and of terbutaline pre-treatment on the β~2~-agonist mediated effects on asthmatic airways
---------------------------------------------------------------------------------------------------------------------------------

### A. Bronchoprotection

Baseline PD~20~ methacholine values after placebo pre-treatment as compared to terbutaline pre-treatment were of a similar magnitude and not statistically different. Figure [1](#F1){ref-type="fig"} shows the back-transformed means and SE\'s for PD~20~methacholine, estimated from the model described above and corrected for baseline. There was no evidence that the shape differences on the log-scale between the dose-response curves for the two treatments vary between the allelic genotypes (interaction: pre-treatment \* fenoterol dose \* genotype, P = 0.23). However, there was evidence that the difference in PD~20~between the two treatments, averaged over fenoterol dose, is related to allelic genotype (interaction: pre-treatment \* genotype, P = 0.0029) and also that the shape of the dose-response curve, averaged over both treatments, varies between the allelic genotypes (interaction: fenoterol dose \* genotype, P = 0.0011). No firm evidence was found that the relative difference in PD~20~between terbutaline pre-treatment and placebo pre-treatment varies over the fenoterol dose (interaction: pre-treatment \* fenoterol dose, P = 0.071), giving additional support for the averaging over fenoterol dose. Averaged over fenoterol dose and genotype, terbutaline pre-treatment reduced PD~20~compared to placebo pre-treatment (P = 0.0026). Terbutaline pre-treatment reduced PD~20~by 53% (95% CI: 31--68%, P = 0.0004) on average for I/III patients and by 66% (95% CI: 35--82%, P = 0.0019) for II/III patients (table [4](#T4){ref-type="table"}). I/II patients showed a comparable, but non-significant reduction. For the other genetic groups, reductions are lower, if existing at all (Table [4](#T4){ref-type="table"}). Adjustment for multiple comparisons -- by for instance the Bonferroni correction -- would not change these conclusions qualitatively. After application of a most conservative approach, i.e. by multiplying the uncorrected P-values by 14, the highest significant P-value of 0.0029 for the pre-treatment \* genotype interaction would still remain below the level of 0.05, namely 0.041. For the within-genotype significant P-values for genotypes I/III and II/III the values would become 0.0056 and 0.0154 respectively.

![PD~20~methacholine (mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated with placebo or terbutaline for two weeks. Averaged over treatment, the shape of the dose response curves varies between the genotypes (p = 0.0011). Averaged over fenoterol dose and genotype, terbutaline pre-treatment reduced PD~20~compared to placebo pre-treatment (P = 0.0026). For the reductions in PD~20~per genotype and associated p-values: see table 4. Drawn line: placebo pre-treatment, dashed line: terbutaline pre-treatment](1465-9921-7-19-1){#F1}

###### 

The reduction in bronchoprotection by fenoterol after terbutaline pre treatment as compared to placebo pre treatment. The response was averaged over fenoterol dose 200--3000 μg. A 50% reduction corresponds to one double dose reduction of PD~20~methacholine. Negative numbers indicate an increase in response.

                     Reduction in PD~20~                      
  ------------------ --------------------- -------- --------- --------
  Allelic genotype   Median                95% CI   P-value   
                                                              
  I/III              53%                   31%      68%       0.0004
  III/III            22%                   -24%     50%       0.30
  II/III             66%                   35%      82%       0.0019
  I/I                -51%                  -139%    4%        0.078
  I/II               50%                   -2%      76%       0.059
  II/II              25%                   -106%    73%       0.58

### B. Recovery by fenoterol of methacholine induced bronchoconstriction

Figure [2](#F2){ref-type="fig"} shows means and SE\'s for FEV~1~measured one hour after fenoterol inhaled directly after the previous PD~20~measurement, as estimated from the model and corrected for baseline. There was no evidence that the shape differences between the dose-response curves for the two treatments vary between the allelic genotypes (interaction: pre-treatment \* fenoterol dose \* genotype, P = 0.48). Neither was there evidence that the difference in FEV~1~between terbutaline pre-treatment and placebo pre-treatment varied over the fenoterol dose (interaction: pre-treatment \* fenoterol dose, P = 0.46), nor that the difference in FEV~1~between the two treatments, averaged over fenoterol dose, is related to allelic genotype (interaction: pre-treatment \* genotype, P = 0.29, see table [5](#T5){ref-type="table"}). There was weak evidence that the shape of the dose-response curve, averaged over both treatments, varies between the allelic genotypes (interaction: fenoterol dose \* genotype, P = 0.060). There was some evidence that averaged over fenoterol dose and genotype terbutaline decreases FEV~1~compared to placebo (P = 0.027) by an estimated 1.58 (SE 0.68) percent points. Only for genotype I/I this decrease reached statistical significance (see table [5](#T5){ref-type="table"}). Adjustment for multiple comparisons, by for instance the Bonferroni correction, reduced all these findings to non-significance.

![FEV~1~(mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated with placebo or terbutaline for two weeks. FEV~1~was measured one hour after fenoterol inhalation, directly after the previous PD~20~measurement. For the reductions in FEV~1~per genotype and associated p-values: see table 5. Drawn line: placebo pre-treatment, dashed line: terbutaline pre-treatment.](1465-9921-7-19-2){#F2}

###### 

Decrease in FEV~1~response to fenoterol after terbutaline pre-treatment as compared to placebo pre-treatment. Response was averaged over fenoterol dose 200--3000 μg. Negative numbers indicate an increase in response.

                     Decrease in FEV~1~(percent points)                      
  ------------------ ------------------------------------ -------- --------- -------
  Allelic genotype   Mean                                 95% CI   P-value   
                                                                             
  I/III              0.71                                 -1.79    3.21      0.57
  III/III            -0.28                                -3.19    2.63      0.85
  II/III             1.84                                 -2.16    5.84      0.36
  I/I                3.02                                 0.09     5.95      0.044
  I/II               -0.80                                -5.28    3.68      0.72
  II/II              6.04                                 -0.18    12.26     0.057

Discussion
==========

This is the first study finding differences between β~2~-AR genotypes in the shape of the dose response relationship of β~2~-AR mediated airway effects in asthmatics *in vivo*. Our data analysis, however, does not allow a further distinction in differences with respect to specific characteristics of the dose response curves, such as the maximum effect at infinite drug dose (Emax) or the dose at which 50% of this maximum effect is obtained (ED50). We found no evidence for an interaction between treatment and genotype influencing the shape of the dose response curve of PD~20~methacholine. Neither was there evidence that the relative differences in PD~20~after terbutaline pre-treatment and placebo pre-treatment vary over the fenoterol dose, as illustrated in figure 5. These latter two findings suggest that, at least with respect to protection against methacholine induced bronchoconstriction, there is a genotype-specific way by which binding of a β~2~-AR agonist to its receptor translates into a clinical response as well as a genotype specific but β~2~-agonist-dose-independent impact of tolerance development on this response. The latter is illustrated by the parallel course of the two dose responses curves within the different genotypes on semilogscale (figure 5).

The functional differences we observed between the allelic genotypes cannot be explained by the known functional consequences of individual SNPs or of haplotypes as delineated *in vitro*. Moreover, the functional phenotype of heterozygotic genotypes does not appear to fit in with that of the homozygotic variants. For instance, in our study genotypes I/I and III/III appear to be resistant to downregulation, while genotype I/III showed a significant degree of downregulation for bronchoprotection by fenoterol. Patients heterozygous on position 19 of the BUP and position 27 of the β~2~-AR, genotypes I/III and II/III, appeared to be most affected by desensitization, with reductions in PD~20~of 53 and 66%, respectively. This is in line with a study that found more desensitization in human airway smooth muscle cells derived from individuals who were heterozygous on position 27 \[[@B15]\]. Our findings illustrate why previous studies focusing on single SNPs in the receptor protein coding block may have yielded negative or even contradictory results. For example, the sub-group of Gly-16 homozygotes consists of three genotypes, III/III, II/III and II/II, with apparently different baseline β~2~-AR agonist mediated responses and propensities to develop downregulation. This implicates that the results of functional studies based solely on variation in amino acid 16 will depend upon the distribution of genotypes within the subgroup of Gly-16 homozygotes.

The absence of a clear-cut relationship between genotypes and functional phenotypes suggests the influence of other yet unidentified co-factors. The identification of one such factor may come from recent findings in mouse models suggesting the existence of \"cross-talk\" in airway smooth muscle between the β~2~-AR system and G~q~-phospholipase C coupled receptors responding to contractile agonists such as methacholine \[[@B22]\]. The findings in this animal model of an increase in cholinergic sensitivity in the absence of chronic β~2~-AR stimulation and vice versa, fit in with our observation of a combination of apparent resistance to downregulation with respect to bronchoprotection (figure [1](#F1){ref-type="fig"} and table [4](#T4){ref-type="table"}) combined with the numerative (and borderline significant) largest degree of loss of bronchodilation (figure [2](#F2){ref-type="fig"} and table [5](#T5){ref-type="table"}) within genotype I/I. Since subjects of this genotype are homozygous Arg16/Arg16, our data in this genotype agree with those of Israel et al\[[@B6]\] who found an increased response to anti-cholinergic therapy in patients of this genotype when they were off β~2~-agonist therapy, in combination with no improvement in lung function when they were on β~2~-agonist therapy.

Some potential limitations of our study need to be discussed. Our active treatment arm consisted of the short acting β~2~-agonist terbutaline, where long-acting β~2~-agonists are nowadays the standard for maintenance bronchodilator therapy in asthma. What matters, however, is whether the degree of \"receptor stimulation\" we obtained is representative for the usual situation in maintenance therapy. In this respect it is relevant that the dose of terbutaline we employed is generally considered to be about therapeutically equivalent to the standard doses of the two long-acting β~2~-agonists formoterol and salmeterol. Furthermore, in a direct comparison 500 μg of terbutaline induced a degree of bronchoprotective subsensitivity of a same order of magnitude as the usually employed doses of formoterol \[[@B23]\]. Using either formoterol or salmeterol would also have limited the extent to which findings with either of this drugs can be generalized in view of their differences in intrinsic efficacy. Relevant in this respect may be that *in vitro*\[[@B24]\] the intrinsic efficacy of terbutaline appears to be in between those of salmeterol and formoterol. Next, the \"test drug\" we employed for the functional studies was fenoterol which is a full β~2~-AR agonist, like formoterol, but unlike salbutamol, salmeterol and also terbutaline that are partial agonists *in vitro*as well as *in vivo*\[[@B21],[@B25],[@B26]\]. It cannot be ruled out that the responses induced by fenoterol are stronger than those that would have been induced by a partial agonist, but it is unlikely that this would have changed the main conclusions of this study. Furthermore, the cohort we studied was of a relatively limited extent, especially in relation to the low numbers of individuals in some subgroups, particularly genotype II/II, and to the uneven presence of the different genotypes in asthmatic cohorts, as also noticed previously \[[@B19]\]. This implicates that the functional implications of especially genotype II/II need further study either in larger groups of patients or after pre-selection of specific genotypes.

Our genotype analyses contained all the SNPs with a known bearing on gene regulation or receptor expression, thus ignoring the three SNPs downstream from basepair +79. In our opinion this is only of limited impact. The SNPs at +252 and +523 are synonymous and so do not result in amino acid substitution, while the one at + 491 is very uncommon. However it cannot be ruled out completely that these three SNPs have an impact on receptor expression e.g. via an effect on mRNA stability.

Our study confirms that downregulation of β~2~-agonist induced airway responses is more easily substantiated for protection towards a bronchoconstrictive stimulus than for bronchodilation form \"baseline\", in this case: recovery form methacholine-induced bronchoconstriction one hour earlier. This is in line with a recent study showing that susceptibility to bronchodilator tolerance increases when the degree of induced bronchoconstriction increases \[[@B27]\]. The degree of tolerance development was much less for FEV~1~and at the most borderline statistically significant for the cohort as a whole.

With respect to the potential clinical implications of our findings it must be realised that for all genotypes some degree of protection against bronchoconstriction remained after two weeks of β~2~-agonist use. After terbutaline pre-treatment, the differences in the dose response curves between genotypes were attenuated and the maximum difference in improvement in PD~20~by the highest dose of fenoterol between the genotypes (II/III versus I/I, figure [1](#F1){ref-type="fig"}) was 1.5 doubling dose, where differences larger than about one doubling dose are generally considered to be clinically significant, in view of the confidence intervals for repeated determinations of methacholine bronchoprovocation thresholds \[[@B28]\]. It is evident that at lower doses of β~2~-agonist, such as normally used by asthmatics in a clinically stable state, the differences are even smaller. Altogether, this implicates that the functional phenotypical differences between the genotypes are probably only of limited clinical significance, at least in stable mild to moderate asthmatics as in our cohort. As we previously argued, such differences are likely to be more relevant in situations with a high state of functional antagonism, such as in asthma exacerbations with severe bronchoconstriction and functionally antagonized receptors by inflammatory mediators, when high doses of short acting β~2~-agonists are used \[[@B21]\].

Conclusion
==========

Our data and analyses in a cohort of asthmatic patients indicate differences between six distinct β~2~-AR allelic genotypes in the shape of the dose response relationship of a β~2~-AR agonist and in the propensity to develop tolerance for these effects. The genotypes are based upon combinations of three limited allelic haplotypes containing the functionally relevant parts of the β~2~-AR gene. The differences we found are statistically significant and functionally relevant only for bronchoprotection when compared to bronchodilation in terms of recovery from methacholine induced bronchoconstriction, and of a magnitude unlikely to be of clinical significance.
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